Friday, September 30, 2022

561.316.3330

Biotechnology News Magazine

Sense Biodetection Expands Leadership Team

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Sense Biodetection innovator in the emerging field of instrument-free molecular diagnostics, has announced the appointment of Simon Turner as Chief Financial Officer and Ryan Roberts as Chief Commercial Officer.

Simon Turner, a veteran international finance and operations leader, joins Sense from Savran Technologies where he was CFO / COO. He has over 20 years’ experience in the diagnostics industry, including 10 years at Oxford Immunotec where he supported the company from early-stage R&D through successful commercial launch, global expansion, and IPO. He is an alumnus of Imperial College London and London Business School.

Roberts brings a diverse executive leadership background including device, software and services in both acute and post- and sub-acute medicine. Among his previous positions, Ryan was CCO at point of care diagnostics company Astute Medical prior to its acquisition by bioMérieux. He joins Sense from Edwards Life Sciences where he was VP Sales, US Critical Care. He is a graduate of the University of Notre Dame and Northwestern’s Kellogg School of Business.

Harry Lamble, CEO said, “I am thrilled to attract talent of Ryan’s and Simon’s caliber to our leadership team. Their experience will be invaluable as we launch our Veros COVID-19 test, the first of our portfolio of innovative molecular testing products that will help make decentralized healthcare a reality.”

Ryan Roberts, CCO commented, “Sense’s Veros products will bring the superior performance of molecular diagnostics closer to the patient to speed diagnosis, improve treatment decisions, and help protect patients’ loved ones and community. I look forward to working with the Sense team to bring our unique tests into the hands of users across the world.”

In conjunction with the rapid growth of its leadership team, Sense has completed commissioning of a substantial new distribution hub near Boston, MA, to support US launch of its Veros COVID-19 test.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine